A Phase 4 interventional study of tacrolimus in Moderate/Severe Atopic Dermatitis, sponsored by Astellas Pharma China, Inc.. Completed at 4 sites in China. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2014-08-05.
Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tacrolimus in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. Tacrolimus · Lymphoma, Follicular.
Among the 26 studies testing tacrolimus in Lymphoma, Follicular, this one is the 5th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2012, is the only one in phase 4, and was the 21st registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →None of the 26 studies testing tacrolimus in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →
Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 2 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 23 · Phase 4 1
First in 1998; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 41 across the 23 interventional studies. Of the 26 that completed or were terminated, 17 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Pharma China, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma China, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Astellas Pharma Inc has 4 studies filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing tacrolimus in Lymphoma, Follicular, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess if proactive, 2 times-weekly application of tacrolimus ointment can extend remission time to relapse and reduce the incidence of disease exacerbation (DE) in paediatric patients over a period of 6 months.
This study includes three periods. First a screening period of up to one week. Second an open-label treatment period of up to six weeks where all participants apply tacrolimus ointment. Third an open-label disease control period of up to six months where half of the participants apply tacrolimus ointment and the other half of the participants do not apply treatment.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
children with moderate/severe atopic dermatitis treated with tacrolimus ointment and continuing to apply tacrolimus ointment during disease control period.
Drug: tacrolimus
children with moderate/severe atopic dermatitis treated with tacrolimus ointment and with no additional treatment during disease control period.
Also known as: Protopic
Time to first DE (disease exacerbation)
Time frame: 6 months of DCP(Disease Control Period) after 2 to 6 weeks of OLP(Open Label Period)
Number of DEs during the DCP
Time frame: 6 months of DCP (Disease Control Period)
Eczema Area and Severity Index (EASI)
Time frame: 6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)
Investigator's Global Assessment (IGA)
Time frame: 6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)
Duration of DE during DCP
Time frame: 6 months of DCP (Disease Control Period)
The overall efficacy during OLP
Time frame: After 2 to 6 weeks of OLP (Open Label Period)
Quantity of tacrolimus ointment used
Time frame: 6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)
Incidence of adverse events
Time frame: 6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)
The record gives a start of Sep 2012, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tacrolimus